for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

June 25 (Reuters) - ERYTECH PHARMA SA:

* ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION

* ERYTECH HAS GRANTED TO SQZ AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP ANTIGEN-SPECIFIC IMMUNE MODULATING THERAPIES EMPLOYING RBC-BASED APPROACHES

* ERYTECH IS ELIGIBLE TO RECEIVE UP TO $57 MLN IN COMBINED UPFRONT AND POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FOR FIRST PRODUCT SUCCESSFULLY DEVELOPED BY SQZ UNDER THIS AGREEMENT

* ERYTECH ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES, AND UP TO $50 MLN IN COMMERCIAL MILESTONE PAYMENTS RELATED TO EACH ADDITIONAL APPROVED PRODUCT OR APPROVED INDICATION

Source text: bit.ly/2Y7qToI

Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up